Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1Expanded_access 1

Sponsor

Cancer Type

Head & Neck 24Lymphoid 20Myeloid 4Other hematologic neoplasm 3Sarcoma 2Gastrointestinal 2Dermatologic 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Sarcoma 1341Glioblastoma 493Gliosarcoma 470Osteosarcoma 364Brain Neoplasms 321Central Nervous System Neoplasms 276Astrocytoma 262Dendritic Cell Sarcoma, Interdigitating 258Gastrointestinal Stromal Tumors 252Neoplasms 231Glioma 230Lymphoma 227Rhabdomyosarcoma 209Neuroblastoma 209Breast Neoplasms 205Sarcoma, Ewing 203Recurrence 202Burkitt Lymphoma 198Lymphoma, Non-Hodgkin 196Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Oligodendroglioma 192Melanoma 183Ovarian Neoplasms 177Lymphoma, Large B-Cell, Diffuse 173Neoplasm Metastasis 172Bone Neoplasms 169Lymphoma, Follicular 158Liposarcoma 144Leukemia, Lymphocytic, Chronic, B-Cell 144Lymphoma, Mantle-Cell 143

Interventions

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Epstein-Barr Virus Infections × Sarcoma × Clear all
NCT04554914 2026-04-27

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Pierre Fabre Medicament

Phase 2 Active not recruiting
190 enrolled
LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT02229981 2017-12-07

ABC-102

RedHill Biopharma Limited

Phase 1/2 Withdrawn
LymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡